Overview

ChemoCentryx has established one of the broadest chemokine-based therapeutics pipelines in the biopharmaceutical industry. We are internally discovering and developing several clinical- or preclinical-stage programs, each targeting distinct chemokine receptors with different small molecule compounds. Our compounds are designed to be highly potent, to minimize off-target side effects as much as possible and to be orally-available for improved patient compliance, as well as ease and efficiency of manufacture.

Our lead product candidate, Traficet-EN™ (CCX282), targeting the CCR9 chemokine receptor, is in a Phase II/III clinical trial for the treatment of patients with moderate-to-severe Crohn's disease as well as in a Phase II clinical trial for the treatment of patients with celiac disease. A second product candidate, CCX140, which targets the CCR2 chemokine receptor, is in a Phase I single-dose escalation trial. CCX354, a CCR1 antagonist, is our third product candidate in the clinic and is currently in a Phase I dose- escalation trial. Our fourth investigational new drug in clinical trials is CCX025 which is the second orally administered compound that inhibits the CCR9 chemokine receptor. In addition, we have several programs, currently in the lead optimization stage, targeting chemokine receptors and chemoattractant receptors.

^ Return to Top